364P Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series

A.R Ahmad,L.M Tho,Y.K.J Chik,W.C.K Lee,T-Y Yang,X Le,A.K Eisert,U Himpe,C De Bondt,J Mazieres,I Petrini,W-S Lam,K Joshi,K Berghoff,S Vlassak,N Karachaliou,A.J Van Der Wekken,T-C Hsia

doi:10.1016/j.annonc.2022.10.402

364P Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series

A.R Ahmad, L.M Tho + Show 16 more

https://doi.org/10.1016/j.annonc.2022.10.402

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Nov 1, 2022
Citations: 1

Affiliation: Hospital Kuala Lumpur, Queen Elizabeth Hospital, Prince of Wales Hospital, The University of Texas MD Anderson Cancer Center, Antwerp University Hospital, Centre Hospitalier Universitaire de Toulouse, Azienda Ospedaliera Universitaria Pisana, University of Groningen

#EGFR-mutant NSCLC #EGFR-TKI Gefitinib + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

MET amplification (METamp) is a mechanism of acquired resistance to EGFR-TKIs. In the INSIGHT trial (NCT01982955), in patients with EGFR-mutant METamp NSCLC and EGFR-TKI resistance, tepotinib (a potent, highly selective MET-TKI) plus gefitinib (EGFR-TKI) improved outcomes in comparison with chemotherapy. We present a case series highlighting the clinical activity of tepotinib plus an EGFR-TKI (gefitinib and/or osimertinib) in patients with EGFR-mutant METamp NSCLC.

Full Text